Gadobenic acid: Difference between revisions
update infobox, description, links, portal |
update infobox |
||
Line 9: | Line 9: | ||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = Multihance |
| tradename = Multihance |
||
| Drugs.com = {{drugs.com| |
| Drugs.com = {{drugs.com|ppa|gadobenate-dimeglumine}} |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_category = |
| pregnancy_category = |
Revision as of 02:05, 30 August 2021
Clinical data | |
---|---|
Trade names | Multihance |
Other names | gadobenate dimeglumine (USAN US) |
AHFS/Drugs.com | Professional Drug Facts |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H28GdN3O11 |
Molar mass | 667.73 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Gadobenic acid (INN, brand name Multihance) is a complex of gadolinium with the ligand BOPTA. In the form of the methylglucamine salt meglumine gadobenate (INNm) or gadobenate dimeglumine (USAN), it is used as a gadolinium-based MRI contrast medium.[3]
BOPTA is a derivative of DTPA in which one terminal carboxyl group, –C(O)OH is replaced by -C–O–CH2C6H5. Thus gadobenic acid is closely related to gadopentetic acid. BOPTA itself was first synthesized in 1995.[4] In the "gadobenate" ion gadolinium ion is 9-coordinate with BOPTA acting as an 8-coordinating ligand. The ninth position is occupied by a water molecule, which exchanges rapidly with water molecules in the immediate vicinity of the strongly paramagnetic complex, providing a mechanism for MRI contrast enhancement. 139La NMR studies on the diamagnetic La-BOPTA2− complex suggest that the Gd complex maintains in solution the same kind of coordination as found, by X-ray crystallography, in the solid state for Gd-BOPTA disodium salt.[4]
References
- ^ "Multihance, 0.5 M solution for injection - Summary of Product Characteristics (SmPC)". (emc). 14 August 2019. Retrieved 29 August 2021.
- ^ "Multihance- gadobenate dimeglumine injection, solution". DailyMed. Retrieved 29 August 2021.
- ^ Sweetman, Sean C., ed. (2009). "Contrast Media". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 1478. ISBN 978-0-85369-840-1.
- ^ a b Uggeri F, Aime S, Anelli PL, Botta M, Brocchetta M, de Haeen C, Ermondi G, Grandi M, Paoli P (1995). "Novel Contrast Agents for Magnetic Resonance Imaging. Synthesis and Characterization of the Ligand BOPTA and Its Ln(III) Complexes (Ln = Gd, La, Lu). X-ray Structure of Disodium (TPS-9-145337286-C-S)-[4-Carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa- 5,8,11-triazatridecan-13-oato(5-)]gadolinate(2-) in a Mixture with Its Enantiomer". Inorganic Chemistry. 34 (3): 633–643. doi:10.1021/ic00107a017. ISSN 0020-1669.
External links
- "Gadobenic acid". Drug Information Portal. U.S. National Library of Medicine.
- "Gadobenate Dimeglumine". Drug Information Portal. U.S. National Library of Medicine.